semaglutide news october 20 2025 Statistics 2026: Ozempic & Wegovy Data, Clinical Outcomes & Market Trends | GoalBMI Wegovy® Lawsuit | July 2026

These results suggest that GSH is not toxic to human keratinocytes and may be safely used on human skin

Theres also the requirement that a GLP-1 oral medication be taken on an empty stomach

ADA Standards of Care 2025) recommend that patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) (or high risk) should be on a GLP-1 RA with proven CV benefit (or an SGLT2 inhibitor) as part of their regimen, independent of A1c, because of the outcome benefits ( [9] ) ( [144] )

The FDA can approve a weight-loss agent before cardiovascular outcome trial data mature a regulatory pathway that sets retatrutide on a plausible course toward a 2026 decision, assuming Phase 3 efficacy and safety data are filed by mid-2025

Additionally, hyperinsulinemia increases oxidative stress, further impairing sperm production and quality [164, 165]